INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring KIT exon 11 + 17 and/or 18 mutations.

Details

Language :

English

ISSN :

0732183X

Volume :

41

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

164018122

Full Text :

https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS11582